Volition Appoints Dr. Ethel Rubin as an Independent Director
VolitionRx (NYSE AMERICAN: VNRX) has appointed Dr. Ethel Rubin as an independent director to its board, effective September 30, 2024. Dr. Rubin, with over 20 years of experience in the life sciences sector, will also serve on the Audit and Compensation Committees. Her extensive background includes leadership roles at BioFortis, CSA Medical, Medtronic, and currently as Head of Ventures at BioHealth Innovation.
Guy Innes, Interim Chair of Volition, highlighted Dr. Rubin's vast knowledge of the life sciences industry and her contribution to launching over 25 commercial products. Dr. Rubin expressed excitement about joining Volition, noting the potential of the company's Nu.Q® technology in both animal and human health sectors, particularly for early detection and monitoring of diseases like cancer and sepsis.
VolitionRx (NYSE AMERICAN: VNRX) ha nominato Dr. Ethel Rubin come direttore indipendente nel suo consiglio, con effetto dal 30 settembre 2024. La Dr. Rubin, con oltre 20 anni di esperienza nel settore delle scienze della vita, servirà anche nei Comitati di Audit e Compensazione. La sua ampia esperienza include ruoli di leadership presso BioFortis, CSA Medical, Medtronic e attualmente come Responsabile delle Iniziative presso BioHealth Innovation.
Guy Innes, Presidente ad interim di Volition, ha sottolineato la vasta conoscenza della Dr. Rubin nel settore delle scienze della vita e il suo contributo nel lancio di oltre 25 prodotti commerciali. La Dr. Rubin ha espresso entusiasmo per l'ingresso in Volition, evidenziando il potenziale della tecnologia Nu.Q® dell'azienda nei settori della salute animale e umana, in particolare per la rilevazione e il monitoraggio precoce di malattie come il cancro e la sepsi.
VolitionRx (NYSE AMERICAN: VNRX) ha nombrado a Dr. Ethel Rubin como directora independiente de su junta, con efecto a partir del 30 de septiembre de 2024. La Dra. Rubin, con más de 20 años de experiencia en el sector de las ciencias de la vida, también formará parte de los Comités de Auditoría y Compensación. Su amplia trayectoria incluye roles de liderazgo en BioFortis, CSA Medical, Medtronic y actualmente como Jefa de Iniciativas en BioHealth Innovation.
Guy Innes, Presidente interino de Volition, destacó el vasto conocimiento de la Dra. Rubin en la industria de las ciencias de la vida y su contribución al lanzamiento de más de 25 productos comerciales. La Dra. Rubin expresó su entusiasmo por unirse a Volition, notando el potencial de la tecnología Nu.Q® de la empresa en los sectores de salud animal y humana, especialmente para la detección temprana y el monitoreo de enfermedades como el cáncer y la sepsis.
VolitionRx (NYSE AMERICAN: VNRX)는 Dr. Ethel Rubin을 이사회의 독립 이사로 임명하며, 임기는 2024년 9월 30일부터 시작된다. Rubin 박사는 생명 과학 분야에서 20년 이상의 경력을 가지고 있으며, 감사 및 보상 위원회에도 참여할 예정이다. 그녀의 광범위한 경력에는 BioFortis, CSA Medical, Medtronic에서의 리더십 역할이 포함되며, 현재 BioHealth Innovation에서 사업 부문장을 맡고 있다.
Volition의 임시 의장인 Guy Innes는 Rubin 박사의 생명 과학 산업에 대한 방대한 지식과 25개 이상의 상업 제품 출시에 기여한 점을 강조했다. Rubin 박사는 Volition에 합류하게 되어 기쁘며, 특히 암과 패혈증과 같은 질병의 조기 발견 및 모니터링을 위한 회사의 Nu.Q® 기술의 잠재력을 주목했다.
VolitionRx (NYSE AMERICAN: VNRX) a nommé Dr. Ethel Rubin en tant que directeur indépendant de son conseil d'administration, à compter du 30 septembre 2024. Dr. Rubin, avec plus de 20 ans d'expérience dans le secteur des sciences de la vie, fera également partie des Comités d'Audit et de Rémunération. Son vaste parcours comprend des postes de direction chez BioFortis, CSA Medical, Medtronic et actuellement en tant que Responsable des Projets chez BioHealth Innovation.
Guy Innes, président par intérim de Volition, a souligné les vastes connaissances de Dr. Rubin dans l'industrie des sciences de la vie et sa contribution au lancement de plus de 25 produits commerciaux. Dr. Rubin a exprimé son enthousiasme à l'idée de rejoindre Volition, notant le potentiel de la technologie Nu.Q® de l'entreprise dans les secteurs de la santé animale et humaine, en particulier pour la détection précoce et le suivi de maladies comme le cancer et la sepsie.
VolitionRx (NYSE AMERICAN: VNRX) hat Dr. Ethel Rubin als unabhängige Direktorin in seinen Vorstand berufen, mit Wirkung zum 30. September 2024. Dr. Rubin bringt über 20 Jahre Erfahrung im Bereich der Lebenswissenschaften mit und wird auch in den Prüfungs- und Vergütungsausschüssen tätig sein. Ihre umfassende Erfahrung umfasst Führungspositionen bei BioFortis, CSA Medical, Medtronic und derzeit als Leiterin der Ventures bei BioHealth Innovation.
Guy Innes, interimistischer Vorsitzender von Volition, hob Dr. Rubins umfangreiche Kenntnisse der Lebenswissenschaftsindustrie sowie ihren Beitrag zur Einführung von mehr als 25 kommerziellen Produkten hervor. Dr. Rubin zeigte sich erfreut über ihren Eintritt bei Volition und bemerkte das Potenzial der Nu.Q®-Technologie des Unternehmens im Bereich der tierischen und menschlichen Gesundheit, insbesondere zur frühzeitigen Erkennung und Überwachung von Krankheiten wie Krebs und Sepsis.
- Appointment of Dr. Ethel Rubin, an experienced life sciences professional, as an independent director
- Dr. Rubin's extensive experience in healthcare innovation and commercialization strategies
- Potential for Nu.Q® technology in both animal and human health sectors
- Nu.Q® technology already commercialized and generating revenue in animal health sector
- None.
Dr. Rubin has over 20 years' experience within the life sciences sector, leading healthcare innovation and commercialization strategies for a wide range of organizations – from early-stage operations to large global corporate businesses.
Early in her career, Dr. Rubin served as Chief Scientific Officer and Operations Officer at BioFortis, Inc. (now Q2 Solutions, a wholly owned subsidiary of IQVIA) and then as Chief Scientific Officer at CSA Medical, Inc. (now Steris Healthcare), where she played a key role in technology development and commercialization. Ethel then moved to Medtronic, plc., where she held multiple leadership roles spanning external innovation, global clinical strategy and medical affairs. Dr. Rubin later took on a role at BioHealth Innovation, Inc. where she currently serves as Head of Ventures, leading a team of strategy and finance consultants who prepare and connect companies with private capital and support the entrepreneurial and investment programs of the National Institutes of Health.
Guy Innes, Interim Chair of Volition, said:
"Dr. Rubin has a vast knowledge and understanding of the life sciences industry and we are delighted to welcome her onto the board at Volition. She has contributed towards the launch of over 25 commercial products, including diagnostics, therapeutics and devices, and has been instrumental in driving collaborations and strategic initiatives. Ethel is ideally placed to support us as we commercialize our epigenetic solutions and scale our operations."
Commenting on her appointment, Dr. Ethel Rubin said:
"I'm delighted to be joining Volition as an independent director. Nu.Q® - the company's transformational nucleosome quantification technology - is already commercialized and generating revenue in the animal health sector. The technology has clear potential for clinical utility within human health too, through early detection and monitoring of diseases such as cancer and sepsis. It's an exciting time for the company and I look forward to supporting Volition's board and leadership team."
Volition is developing simple, easy-to-use, cost-effective blood tests to help diagnose and monitor a range of life-altering diseases in both humans and animals. For more information about Volition's technology go to: www.volition.com.
About Volition
Volition is a multi-national company focused on advancing the science of epigenetics. Volition is dedicated to saving lives and improving outcomes for people and animals with life-altering diseases through earlier detection, as well as disease and treatment monitoring.
Through its subsidiaries, Volition is developing and commercializing simple, easy to use, cost-effective blood tests to help diagnose and monitor a range of diseases, including some cancers and diseases associated with NETosis, such as sepsis. Early diagnosis and monitoring have the potential not only to prolong the life of patients, but also improve their quality of life.
Volition's research and development activities are centered in
The contents found at Volition's website address are not incorporated by reference into this document and should not be considered part of this document. Such website address is included in this document as an inactive textual reference only.
Media Enquiries:
Louise Batchelor/Debra Daglish, Volition, mediarelations@volition.com +44 (0)7557 774620
Safe Harbor Statement
Statements in this press release may be "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, that concern matters that involve risks and uncertainties that could cause actual results to differ materially from those anticipated or projected in the forward-looking statements. Words such as "expects," "anticipates," "intends," "plans," "aims," "targets," "believes," "seeks," "estimates," "optimizing," "potential," "goal," "suggests," "could," "would," "should," "may," "will" and similar expressions identify forward-looking statements. These forward-looking statements relate to, among other topics, the potential uses, benefits and effectiveness of Volition's Nu.Q® technology platform. Volition's actual results may differ materially from those indicated in these forward-looking statements due to numerous risks and uncertainties, including, without limitation, results of studies testing the efficacy of its tests. For instance, if Volition fails to develop and commercialize diagnostic, prognostic or disease monitoring products, it may be unable to execute its plan of operations. Other risks and uncertainties include Volition's failure to obtain necessary regulatory clearances or approvals to distribute and market future products; a failure by the marketplace to accept the products in Volition's development pipeline or any other diagnostic, prognostic or disease monitoring products Volition might develop; Volition's failure to secure adequate intellectual property protection; Volition will face fierce competition and Volition's intended products may become obsolete due to the highly competitive nature of the diagnostics and disease monitoring market and its rapid technological change; downturns in domestic and foreign economies; and other risks, including those identified in Volition's most recent Annual Report on Form 10-K and Quarterly Reports on Form 10-Q, as well as other documents that Volition files with the Securities and Exchange Commission. These statements are based on current expectations, estimates and projections about Volition's business based, in part, on assumptions made by management. These statements are not guarantees of future performance and involve risks, uncertainties and assumptions that are difficult to predict. Forward-looking statements are made as of the date of this press release, and, except as required by law, Volition does not undertake an obligation to update its forward-looking statements to reflect future events or circumstances.
Nucleosomics™, Capture-PCR™ and Nu.Q® and their respective logos are trademarks and/or service marks of VolitionRx Limited and its subsidiaries. All other trademarks, service marks and trade names referred to in this press release are the property of their respective owners.
Photo: https://mma.prnewswire.com/media/2519421/VolitionRx.jpg
View original content to download multimedia:https://www.prnewswire.com/news-releases/volition-appoints-dr-ethel-rubin-as-an-independent-director-302262820.html
SOURCE VolitionRx Limited
FAQ
Who is the new independent director appointed to VolitionRx 's board?
What committees will Dr. Ethel Rubin serve on at VolitionRx (VNRX)?
What is Dr. Ethel Rubin's current role outside of VolitionRx (VNRX)?
What is the potential application of VolitionRx's (VNRX) Nu.Q® technology?
